Dataset Information


ALK and IGF-1R as independent targets in crizotinib resistant lung cancer.

ABSTRACT: ALK positive non-small cell lung cancer is highly responsive to ALK inhibitors such as crizotinib, but drug resistance typically develops within a year of treatment. In this study we investigated whether IGF-1R is an independent druggable target in ALK-positive lung cancer cells. We confirmed that combination ALK and IGF-1R inhibitor treatment is synergistically cytotoxic to ALK-positive lung cancer cells and that this remains the case for at least 12 days after initial exposure to crizotinib. ALK-positive cells with acquired resistance to crizotinib did not acquire cross-resistance to IGF-1R inhibition, though combination treatment in the resistant cells gave additive rather than synergistic cytotoxicity. We concluded that IGF-1R is an independent druggable target in ALK-positive lung cancer and support the trial of combination treatment.


PROVIDER: S-EPMC5654778 | BioStudies | 2017-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5085167 | BioStudies
2014-01-01 | S-EPMC4159407 | BioStudies
2019-01-01 | S-EPMC6906283 | BioStudies
2018-01-01 | S-EPMC5783011 | BioStudies
1000-01-01 | S-EPMC4796802 | BioStudies
2015-01-01 | S-EPMC4638315 | BioStudies
2011-01-01 | S-EPMC3265718 | BioStudies
2020-01-01 | S-EPMC7068933 | BioStudies
1000-01-01 | S-EPMC5912135 | BioStudies
2016-01-01 | S-EPMC5233871 | BioStudies